Corporation
Pharmascience Inc.
- Meetings this Parliament
- 175
- With MPs
- 20
- Since Nov 2021
- 212
- Active registrations
- 1
Most recent reported meeting: Oct 13, 2026.
Lobbying by Pharmascience Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since Oct 20, 2026 Receives government funding
Filed by David Goodman, Chief Executive Officer
Lobbyists
- David Goodman · Executive Chairman
- Julie Seïde · Director, Government Affairs
- Ken Gagnon · Senior Manager, Government Affairs
- Morris Goodman · Co-Founder
Institutions they may lobby: Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Services and Procurement Canada (PSPC), Transport Canada (TC)
What they're lobbying on (8)Hide details
- Policies aimed at reinforcing pharmaceutical supply chain.
- Discussion regarding the launch of new branded product in the rare disease space
- Improvements to the supports offered by the federal government to support R&D; in particular, generic drug research and development.
- Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.
- Policies aimed at facilitating generic drug repurposing.
- Discussion on the opioid crisis and the Health minister's expectations from pharmaceutical manufacturers
- Discussion of regulatory impediments to the launch of pediatric formulations of branded and generic products.
- Discussion of a possible Therapeutics Products Directorate ("TPD") workstream on complex generics regulatory pathways.
Registration 725814-234102-38. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by David Goodman (205), Martin Arès (7).
-
Reported by David Goodman · In-house (corporation)
- Cédrick Devedeux Delorme · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
- Manuela Tomic · Conseillère principale en politiques, Innovation, Science and Economic Development Canada (ISED)
Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.
-
Reported by David Goodman · In-house (corporation)
- Mélanie Joly · Ministre de l'Industrie et ministre responsable pour le développement économique Canada pour les régions du Québec, Innovation, Science and Economic Development Canada (ISED)
- Cédrick Devedeux Delorme · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Policies aimed at reinforcing pharmaceutical supply chain. Read more
Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.
-
Reported by David Goodman · In-house (corporation)
- Patrice Lepage · Analyste princ. d'investissements, Innovation, Science and Economic Development Canada (ISED)
- Sean Letourneau · Directeur, Innovation, Science and Economic Development Canada (ISED)
- Alhadji Mamat · Gestionnaire princ. d'investissements, Innovation, Science and Economic Development Canada (ISED)
- Éric Sabourin · Analyste princ. d'investissements, Innovation, Science and Economic Development Canada (ISED)
and 1 moreShow fewer
- Catherine Martinelli · Analyste des risques opérationnels, Innovation, Science and Economic Development Canada (ISED)
Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.
-
Reported by David Goodman · In-house (corporation)
- Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
- Laura Bourns · Directeur, Finance Canada (FIN)
- Nadeen Abd El Aal · Analyste, Innovation, Science and Economic Development Canada (ISED)
- Jimmy Lou · economiste, Finance Canada (FIN)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Rodrigo Arancibia · Senior Director, Innovation, Science and Economic Development Canada (ISED)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Mélanie Joly · Ministre de l'Industrie et ministre responsable pour le développement économique Canada pour les régions du Québec, Innovation, Science and Economic Development Canada (ISED)
- Manuela Tomic · Conseillère principale en politiques, Innovation, Science and Economic Development Canada (ISED)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Manuela Tomic · Conseillère principale en politiques, Innovation, Science and Economic Development Canada (ISED)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Caroline Ménard · Manager, Préparation aux crises sanitaires Canada, Innovation, Science and Economic Development Canada (ISED)
Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.
-
Reported by David Goodman · In-house (corporation)
- Ritu Banerjee · Sous-ministre adjoint(e), Innovation, Science and Economic Development Canada (ISED)
- Caroline Ménard · Manager, Préparation aux crises sanitaires Canada, Innovation, Science and Economic Development Canada (ISED)
Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.
-
Reported by David Goodman · In-house (corporation)
- Arianne Reza · Deputy Minister, Public Services and Procurement Canada (PSPC)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Manuela Tomic · Conseillère principale en politiques, Innovation, Science and Economic Development Canada (ISED)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Ritu Banerjee · Sous-ministre adjoint(e), Innovation, Science and Economic Development Canada (ISED)
- Jocelyne Voisin · Sous-ministre adjointe principale, Health Canada (HC)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Patrice Lepage · Analyste principal d'investissements, Innovation, Science and Economic Development Canada (ISED)
- Sean Letourneau · Directeur, Innovation, Science and Economic Development Canada (ISED)
- Alhadji Mamat · Gestionnaire princ. d'investissements, Innovation, Science and Economic Development Canada (ISED)
- Catherine Martinelli · Analyste des risques opérationnels, Innovation, Science and Economic Development Canada (ISED)
Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.
-
Reported by David Goodman · In-house (corporation)
- Jocelyne Voisin · Sous-ministre adjointe principale, Health Canada (HC)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Jacques Ramsay · Député
- Joël Raby Fernandes · Adjoint parlementaire, House of Commons
- Jean-Sébastien Côté · Gestionnaire de bureau, House of Commons
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Mélanie Joly · Ministre de l'Industrie et ministre responsable pour le développement économique Canada pour les régions du Québec, Innovation, Science and Economic Development Canada (ISED)
- Jacques Ramsay · Député
- Marjorie Michel · Ministre de la Santé, Health Canada (HC)
- Manuela Tomic · Conseillère principale en politiques, Innovation, Science and Economic Development Canada (ISED)
and 3 moreShow fewer
- Joël Raby Fernandes · Adjoint parlementaire, House of Commons
- Justine Frame · Conseillère en politiques, Health Canada (HC)
- Shalene Curtis-Micallef · Sous-ministre, Health Canada (HC)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Manuela Tomic · Conseillère principale en politiques, Innovation, Science and Economic Development Canada (ISED)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Robyn Brake · Conseillère principale en politiques, Innovation, Science and Economic Development Canada (ISED)
- Tanya Ramsamy · Directrice executive, Health Canada (HC)
- Alysha Croker · Directrice, Health Canada (HC)
- Christiane Grise-Bard · Directrice associée par intérim, Health Canada (HC)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Manuela Tomic · Conseillère principale en politiques, Innovation, Science and Economic Development Canada (ISED)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Miro Froehlich · Directeur des politiques, Privy Council Office (PCO)
- Manuela Tomic · Conseillère principale en politiques, Innovation, Science and Economic Development Canada (ISED)
- Isabelle Buchanan · Conseillère en politiques, Global Affairs Canada (GAC)
- Jasmine Gill · Directrice des politiques, Global Affairs Canada (GAC)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Erin Campbell · Directrice, Innovation, Science and Economic Development Canada (ISED)
- Brad Jenkins · Conseiller expert en recherche et analyse des politique, Innovation, Science and Economic Development Canada (ISED)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Miro Froehlich · Directeur des politiques, Privy Council Office (PCO)
- Manuela Tomic · Conseillère principale en politiques, Innovation, Science and Economic Development Canada (ISED)
- Jasmine Gill · Directrice des politiques, Global Affairs Canada (GAC)
- Isabelle Buchanan · Conseillère en politiques, Global Affairs Canada (GAC)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Miro Froehlich · Directeur des politiques, Privy Council Office (PCO)
- Manuela Tomic · Conseillère principale en politiques, Innovation, Science and Economic Development Canada (ISED)
- Isabelle Buchanan · Conseillère en politiques, Global Affairs Canada (GAC)
- Jasmine Gill · Directrice des politiques, Global Affairs Canada (GAC)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Erin Campbell · Directrice, Innovation, Science and Economic Development Canada (ISED)
Policies aimed at reinforcing pharmaceutical supply chain.
-
Reported by David Goodman · In-house (corporation)
- Manuela Tomic · Conseillère principale en politiques, Innovation, Science and Economic Development Canada (ISED)
Policies aimed at reinforcing pharmaceutical supply chain.
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.